Stockpolly
Search
Delisting risk
AKTX · NASDAQ · Biotechnology

Akari Therapeutics (ADR) (AKTX)

Develops preclinical oncology antibody-drug conjugates based on its PH1 payload platform.

$10.02
Pre-market−0.13 (−1.28%)
At close$10.15(−2.12%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Cost of revenue000000000000
Gross profit000000000000
3567354373165
Research & development052301110112
334223322223
Selling & marketing004000000000
General & administrative330223322223
Other expenses0−302110050120
Operating income−3−5−6−7−3−5−4−3−7−3−16−5
010002010−200
Interest income0—000000—000
Interest expense000000000100
Other non-operating income0−1000−20−101−10
Income before tax−3−4−6−8−3−4−4−2−7−5−15−5
Income tax expense00000000−10−10
Net income from continuing operations−3−4−6−8−3−4−4−2−6−5−14−5
Net income−3−4−6−8−3−4−4−2−6−5−14−5
EPS, basic−$1,136.00−$1,880.00−$1,656.00−$1,608.00−$472.00−$392.00−$272.00−$120.00−$392.00−$248.00−$688.00$0.00
EPS, diluted−$1,136.00−$1,880.00−$1,656.00−$1,608.00−$472.00−$392.00−$272.00−$120.00−$392.00−$248.00−$688.00$0.00
Weighted average shares, basic000000000002
Weighted average shares, diluted000000000002
EBITDA−3−4−6−8−3−4−4−2−7−4−15−5
Depreciation & amortization000000000000
EBIT−3−4−6−8−3−4−4−2−7−4−15−5